CEL-SCI has reported that its LEAPS COV-19 peptides achieved a 40% survival rate in transgenic mouse models versus 0% survival in the two control groups in preclinical studies.

The peptides were delivered as a therapeutic treatment following the breakout of the SARS-CoV-2 virus.

LEAPS target the non-mutating part of the virus and elicit cytolytic T cell responses to virus-infected cells and immunomodulating responses.

The studies were conducted at the University of Georgia Center for Vaccines and Immunology.

The University of Georgia scientists and CEL-SCI’s scientific team carried out a challenge study in human(h) ACE2 receptor transgenic mice infected with a SARS-CoV-2 virus dose sufficient to cause death in all animals within eight days.

This transgenic animal model is ideal to study Covid-19 as the mice express the molecule that provides entry for the virus into human cells, CEL-SCI noted.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Virus infection is optimised in this animal model providing an ideal system to analyse vaccine-induced immune protection or therapy against the infection in humans.

In the preclinical study, the animals were treated with LEAPS COV-19 peptides one day after administering a dose of SARS-CoV-2.

Data showed that 40% of the LEAPS-treated mice were alive, recovering and regained lost weight, attaining over 90% of their starting weight, by the end of the study.

Mice in the two control groups, however, lost 20% or more of their body weight by the end of the study and died between day five and day eight.

The therapy was 95% statistically significant.

Apart from this, another study analysing the preventive property of using LEAPS against the disease showed similar findings with a slightly lower level of statistical significance.

CEL-SCI CEO Geert Kersten said: “A critical benefit of LEAPS’ mechanism of action is its focus on highly conserved portions within the nucleoprotein of the virus.

“This may become very important as mutations in SARS-CoV-2 that could limit a vaccine or treatment induced protection have already been reported.”